Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. - Wikidata - awgldk - TriplyDB

Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.

Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.

http://www.wikidata.org/entity/Q36553493

about

Cytoreductive surgery in the era of targeted molecular therapy Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.Cytoreductive nephrectomy in the modern era: Predictors of use, morbidity, and survival.Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.Cytoreductive Surgery in the Management of Renal Tumours: Rationale, Current Evidence and Future Perspectives.Mortality trends and the impact of lymphadenectomy on survival for renal cell carcinoma patients with distant metastasis.Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.Surgical management of metastatic renal cell carcinoma in the era of targeted therapies.New challenges in kidney cancer management: integration of surgery and novel therapies.Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.[Systemic treatment of metastatic renal cell carcinoma: change of paradigms after introduction of targeted therapy].Cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based analysis of perioperative outcomes according to clinical stage.Role of cytoreductive nephrectomy in the targeted therapy era: A systematic review and meta-analysis.Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis.[Should cytoreductive nephrectomy be performed in patients with metastatic renal cell carcinoma and what is the scientific rationale?]

P2860

Q26774134-FA3AEC30-22C8-48E8-967A-E5DB8AE8BBEF Q26783520-9E80664B-B121-4012-8AB6-DDB4F4ECF777 Q31109447-86D9A094-6E71-4044-AC15-AC29C6667A13 Q33665043-7A51FF57-8747-452B-BBCF-37765625F2B8 Q33740717-AF6AB926-F7F2-4273-A322-EA8AE3991B01 Q36261983-04B779BD-3505-4C5A-813B-E720DC5BBA2A Q37515882-04CF25DB-C2D5-4D15-888C-D6A9DCC4B12D Q37671681-98F0C777-AF63-4EEF-BBF8-BEE1B358C100 Q38202061-45252B60-1451-409F-97B1-C2C9912E451D Q38381788-1C414829-F220-42EF-B5B8-7E802199E088 Q38543085-460B7B75-CDDD-41D1-84CA-CBE7D80F66D8 Q38582600-53284443-48B6-4590-BFAA-5BB5AEF7758F Q39505971-A86D7539-A01A-4487-8FB9-BFDDA135831E Q43810315-8DD570DC-52F1-42C0-B985-CC4B20532DD1 Q44217603-808521CA-D6BA-41C8-9B46-8E2896520B81 Q48246088-EB42FCD4-A026-4E37-B1F0-034DAB3C7C74 Q50217752-D38C3690-4353-4B6D-BCD7-43A683A6B39C Q50791794-89EFD25A-C11A-4D2D-B94F-655693EBFBBC

P2860

Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.

http://www.wikidata.org/entity/Q36553493

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Cytoreductive nephrectomy for ...... nited States: a SEER analysis.

@ast

Cytoreductive nephrectomy for ...... nited States: a SEER analysis.

@en

type

label

Cytoreductive nephrectomy for ...... nited States: a SEER analysis.

@ast

Cytoreductive nephrectomy for ...... nited States: a SEER analysis.

@en

prefLabel

Cytoreductive nephrectomy for ...... nited States: a SEER analysis.

@ast

Cytoreductive nephrectomy for ...... nited States: a SEER analysis.

@en

P1433

Q36553493-093889FF-7A6B-4F17-824D-BAAB93814EBA

P1476

Q36553493-E08EA7D3-EB5A-48F1-965B-5D98976E245B

P2093

Q36553493-1904DB00-4DC0-4359-8CAE-8C556C1965B2

Q36553493-1B6025AD-9FB7-4342-B498-EF8B60853B5F

Q36553493-2603F992-E677-4E3D-82AC-6C0A8363CF68

Q36553493-3F482BC5-1B95-4D3C-AAEF-05DAA45B3CDC

Q36553493-6A43D343-C693-4CCC-A3C9-CBA97C8BB020

Q36553493-7A90950D-4A4B-43F1-8902-40809414AF90

Q36553493-87FC6FD7-0653-42B3-A2DA-57FEC9E551A2

Q36553493-B0D13431-E8F6-4D5E-B926-D1D02C15D9FB

Q36553493-E69A01C9-FFCF-4928-90CA-82215CF82073

Q36553493-F3E0655F-D0AA-4E3D-A66C-943E075D1CA0

P2860

Q36553493-023C9214-8BB0-4CC7-9E52-9F95E31C579F

Q36553493-1345AFA4-09FC-42A7-B6D6-F52C577F0705

Q36553493-41B6A552-C557-4DE2-9218-00C8BD872468

Q36553493-438EDB35-9E8A-452D-894F-59378905B1BC

Q36553493-5FC66364-03F3-4F85-AEEF-FEA0C5132BBB

Q36553493-65812946-B7F9-46C4-B8C0-F871DD4ECF64

Q36553493-89C84535-96DC-425A-B5C9-B89281728B6E

Q36553493-8B4E8FB9-F364-4982-B83D-19FF8FCD8E93

Q36553493-900D9014-3919-4429-B918-8BD2C7D24C18

Q36553493-9D2DCBC9-DAF9-4D52-8E3F-C6E6A01B71B6

P2888

Q36553493-C2D991D9-7A60-4A86-A3D3-24914265A64D

P304

Q36553493-7D2FCF74-4D5A-49E6-80D9-4D46A4BF4934

P31

Q36553493-03C30BEC-E778-479F-B613-B8AD38309EDF

P356

Q36553493-9964A333-F2AB-4A5D-B83F-F772ACC18843

P433

Q36553493-1BBCD4CF-1A36-4AD9-AE46-8DE6175AD72E

P478

Q36553493-80636D21-19FA-4139-B327-8DC192B293E8

P50

Q36553493-3F329710-4ED8-48EC-998E-A7E681DE2BE1

Q36553493-7776343D-40E7-4085-B65F-F22C9045DD26

P577

Q36553493-CBC2DEC9-1A5F-4316-8611-0ABCA6D7B90B

P698

Q36553493-184A0872-B60C-4F7F-9025-A49DF9B51C57

P932

Q36553493-F30EE035-B48E-44BA-898D-762A7BE161B9

P356

S00345-012-1001-3

P1433

World Journal of Urology

P1476

Cytoreductive nephrectomy for ...... nited States: a SEER analysis.

@en

P2093

Benjamin A Gartrell

http://www.w3.org/2001/XMLSchema#string

Che-kai Tsao

http://www.w3.org/2001/XMLSchema#string

Erin L Moshier

http://www.w3.org/2001/XMLSchema#string

Guru Sonpavde

http://www.w3.org/2001/XMLSchema#string

James H Godbold

http://www.w3.org/2001/XMLSchema#string

Matthew D Galsky

http://www.w3.org/2001/XMLSchema#string

Max Kates

http://www.w3.org/2001/XMLSchema#string

Michael A Palese

http://www.w3.org/2001/XMLSchema#string

Simon J Hall

http://www.w3.org/2001/XMLSchema#string

William K Oh

http://www.w3.org/2001/XMLSchema#string

P2860

Immunotherapy for advanced renal cell cancer

Race, gender, and partnership in the patient-physician relationship.

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy

Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study.

Impact of breast carcinoma on African-American women: the Detroit experience.

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma

Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival

The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

P2888

s00345-012-1001-3

P304

1535-1539

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00345-012-1001-3

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Alexander C Small

Juan P Wisnivesky

P577

2012-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23223962

http://www.w3.org/2001/XMLSchema#string

P932

4744480

http://www.w3.org/2001/XMLSchema#string